LINAGLIPTIN

Search structure
Trade Names:
Synonyms:
Status: Approved (2011)
Entry Type: Small molecule
Molecule Category: Parent
ATC: A10BH05
UNII: 3X29ZEJ4R2

Structure
InChI Key LTXREWYXXSTFRX-QGZVFWFLSA-N
Smile CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
InChI
InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C25H28N8O2
Molecular Weight 472.55
AlogP 1.15
Hydrogen Bond Acceptor 10.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 4.0
Polar Surface Area 116.86
Molecular species BASE
Aromatic Rings 4.0
Heavy Atoms 35.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Dipeptidyl peptidase IV inhibitor
Primary Target
dipeptidyl peptidase 4
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Protease Serine protease Serine protease SC clan Serine protease S9B subfamily
3.1 0.1-15.37 0.0066-5.3 340 96.24
Enzyme Protease Serine protease
3.1 0.1-15.37 0.0066-5.3 340 96.24
Enzyme Transferase
- - - - 8.415-14.36
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb
- - - - -2.55--0.81
Ion channel Voltage-gated ion channel Potassium channels Voltage-gated potassium channel
- - - - 97
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Acetylcholine receptor
- 295-300 - - -
Transcription factor
- 41000-45000 - - -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 3.39
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters
- - - - 0
Transporter Primary active transporter ATP-binding cassette ABCG subfamily
- - - - 24.7

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Severe Acute Respiratory Syndrome 3 D045169 ClinicalTrials
Respiratory Tract Diseases 3 D012140 ClinicalTrials
Esophageal Neoplasms 1 D004938 ClinicalTrials
Renal Insufficiency 1 D051437 ClinicalTrials
Schizophrenia 1 D012559 ClinicalTrials
Adenocarcinoma 1 D000230 ClinicalTrials
Stomach Neoplasms 1 D013274 ClinicalTrials
Hypertension 1 D006973 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 1 D002289 ClinicalTrials

Related Entries

Scaffolds

Mixture
Mixture
Mixture

Side Effects from Label

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Gastrointestinal disorders
12.7
General disorders and administration site conditions
8.03
Investigations
7.93
Skin and subcutaneous tissue disorders
7.77
Nervous system disorders
7.1
Respiratory, thoracic and mediastinal disorders
6.48
Cardiac disorders
5.92
Metabolism and nutrition disorders
5.54
Vascular disorders
5.43
Musculoskeletal and connective tissue disorders
4.34
Immune system disorders
4.1
Infections and infestations
3.98
Renal and urinary disorders
3.66
Injury, poisoning and procedural complications
3.06
Endocrine disorders
2.97
Psychiatric disorders
2.9
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
2.46

Cross References

Resources Reference
CAS NUMBER 668270-12-0
ChEBI 68610
ChEMBL CHEMBL237500
DrugBank DB08882
DrugCentral 4175
FDA SRS 3X29ZEJ4R2
Guide to Pharmacology 6318
PDB 356
PubChem 10096344
SureChEMBL SCHEMBL160188
ZINC ZINC000003820029
CONTENTS